Attovia Therapeutics, Inc.

NASDAQ:ATTO

Biotechnology

Healthcare
$15.53 -1.20%

-$0.18 today

Market cap
$709.92M
Beta
0.00
P/E (TTM)
-15.9
EPS (TTM)
-$0.86
52W Low $14.23High $28.00

Volume 0.34M

Average 0.45M

ATTO EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Attovia Therapeutics, Inc.NASDAQ: ATTO

EBITDA · Q2 FY2026 · quarter ended Jun 2026

EBITDA of -$21.56M in Q2 FY2026

Q2 FY2026 EBITDA was -$21.56M.

Context

  • EBITDA amounted to 4915.2% of revenue in FY2025.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$21.56M-9.4% QoQ
Last fiscal yearDec 2025
-$66.36M-60.9% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-60.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

EBITDA history

USD · from the income statement

Latest · FY2025
(66.36M) USD
Year-over-year change
-60.9%

EBITDA vs competitors

How ATTO compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -60.9% is the 7th highest of 10, against a peer median of -31.5%.
  • EBITDA amounts to 4915.2% of revenue for ATTO, versus a peer median of 795.1%.
ATTO Competitors
EBITDA for ATTO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANABAnaptysBio, Inc.LTM Mar 2026$58.49M USD+176.6%—25.2%
QTTBQ32 Bio Inc.LTM Mar 2026$22.15M USD+154.8%—41.2%
AGMBAgomAb Therapeutics N.V. American Depositary SharesFY2024-€45.89M EUR-286.3%——
CNTBConnect Biopharma Holdings LimitedFY2025-$54.58M USD-270.2%—85279.7%
ATTOAttovia Therapeutics, Inc.FY2025-$66.36M USD-60.9%—4915.2%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026-$70.61M USD-31.5%—843.9%
EVMNEvommune, Inc.LTM Mar 2026-$74.62M USD——746.2%
ZURAZura Bio LimitedLTM Mar 2026-$75.38M USD-21.4%——
ORKAOruka Therapeutics, Inc.LTM Sep 2026-$161.31M USD-42.5%——
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026-$245.81M USD-69.1%——
ALMSAlumis Inc. Common StockLTM Jun 2026-$442.87M USD-9.5%—5986.3%
Peer median (excluding ATTO) —-31.5%—795.1%

Competitors are the stored peer set for ATTO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2024
Dec 2024
FY2025
Dec 2025
Revenue01.35M
Cost of Revenue313K804K
Gross Profit(313K)546K
Gross Margin—40.4%
Research & Development33.86M54.15M
Selling, General & Admin7.38M13.55M
Operating Expenses41.24M67.71M
Depreciation & Amortization313K804K
EBITDA(41.24M)(66.36M)
EBITDA Margin—-4915.2%
Operating Income(41.55M)(67.16M)
Operating Margin—-4974.7%
Interest Income3.44M6.63M
Interest Expense00
Other Income / Expenses1.75M6.53M
Income Before Tax(39.8M)(60.63M)
Pre-Tax Margin—-4490.9%
Income Tax Expense00
Net Income(39.8M)(60.63M)
Net Margin—-4490.9%
EPS (Basic)(1.05)(1.42)
EPS (Diluted)(1.05)(1.42)
Weighted Avg Shares43.03M43.03M
Weighted Avg Shares (Diluted)43.03M43.03M

Attovia Therapeutics, Inc.

NASDAQ:ATTO

Intrinsic Alpha fair value

Locked

Current Price

$15.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.